Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
Edwards Pradenas,
Silvia Marfil,
Víctor Urrea,
Macedonia Trigueros,
Tetyana Pidkova,
Anna Pons-Grífols,
Raquel Ortiz,
Carla Rovirosa,
Ferran Tarrés-Freixas,
Carmen Aguilar-Gurrieri,
Ruth Toledo,
Anna Chamorro,
Marc Noguera-Julian,
Lourdes Mateu,
Ignacio Blanco,
Eulàlia Grau,
Marta Massanella,
Jorge Carrillo,
Bonaventura Clotet,
Benjamin Trinité,
Julià Blanco
Affiliations
Edwards Pradenas
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Silvia Marfil
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Víctor Urrea
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Macedonia Trigueros
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Tetyana Pidkova
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Anna Pons-Grífols
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Raquel Ortiz
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Carla Rovirosa
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Ferran Tarrés-Freixas
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Carmen Aguilar-Gurrieri
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Ruth Toledo
Infectious Diseases Department, Fight AIDS and Infectious Diseases Foundation (FLS), Germans Trias i Pujol Hospital, 08916 Badalona, Catalonia, Spain
Anna Chamorro
Infectious Diseases Department, Fight AIDS and Infectious Diseases Foundation (FLS), Germans Trias i Pujol Hospital, 08916 Badalona, Catalonia, Spain
Marc Noguera-Julian
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Lourdes Mateu
Infectious Diseases Department, Fight AIDS and Infectious Diseases Foundation (FLS), Germans Trias i Pujol Hospital, 08916 Badalona, Catalonia, Spain
Ignacio Blanco
Germans Trias i Pujol Hospital, 08916 Badalona, Catalonia, Spain
Eulàlia Grau
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Marta Massanella
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain; University of Vic–Central University of Catalonia (UVic-UCC), 08500 Vic, Catalonia, Spain; CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain
Jorge Carrillo
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain
Bonaventura Clotet
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain; Infectious Diseases Department, Fight AIDS and Infectious Diseases Foundation (FLS), Germans Trias i Pujol Hospital, 08916 Badalona, Catalonia, Spain; University of Vic–Central University of Catalonia (UVic-UCC), 08500 Vic, Catalonia, Spain
Benjamin Trinité
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain; Corresponding author
Julià Blanco
IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Catalonia, Spain; University of Vic–Central University of Catalonia (UVic-UCC), 08500 Vic, Catalonia, Spain; CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain; Corresponding author
Summary: The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden neutralizing responses. To assess the contribution of vaccines and natural infection, we cross-sectionally analyzed plasma neutralization titers of six groups of individuals, organized according to the number of vaccines they received and their SARS-CoV-2 infection history. Two doses of vaccine had a limited capacity to generate cross-neutralizing antibodies against Omicron variants of concern (VOCs) in uninfected individuals, but efficiently synergized with previous natural immunization in convalescent individuals. In contrast, booster dose had a critical impact on broadening the cross-neutralizing response in uninfected individuals, to level similar to hybrid immunity, while still improving cross-neutralizing responses in convalescent individuals. Omicron breakthrough infection improved cross-neutralization of Omicron subvariants in non-previously infected vaccinated individuals. Therefore, ancestral Spike-based immunization, via infection or vaccination, contributes to broaden SARS-CoV-2 humoral immunity.
